AtaGenix Laboratories
High-Quality Custom Peptides • Advanced Modifications • Worldwide Delivery
Professional solid-phase peptide synthesis with years of expertise. We deliver high-quality peptides tailored to your specific research needs.
Specialized modification services for research applications including antibody development and functional studies.
Professional peptide-carrier protein conjugation services for immunization and antibody production.
Service Details | Delivery Time | Deliverables | Pricing |
---|---|---|---|
Standard Peptides Up to 30 amino acids |
2 weeks | • Custom peptide • HPLC analysis report • MS verification report |
Request Quote |
Extended Services Longer sequences & gram-scale |
Consultation required | • Custom peptide • HPLC analysis report • MS verification report |
With over a decade of experience in solid-phase peptide synthesis, we provide reliable, high-quality peptides for research institutions, pharmaceutical companies, and biotechnology firms worldwide. Our state-of-the-art facilities ensure consistent quality and fast delivery times.
Get professional peptide synthesis services tailored to your research needs. Our experts are ready to help you achieve your scientific goals.
A 2017 study developed a high-affinity anti-HE4 monoclonal antibody (9C3) using AtaGenix’s advanced mammalian expression and hybridoma platforms. This breakthrough enhances ovarian cancer diagnostics by targeting the HE4 biomarker with high specificity, offering potential for early detection and therapy.
This article highlights a 2021 Small Methods study that identified immunogenic peptides in the SARS-CoV-2 spike protein and isolated neutralizing monoclonal antibodies from COVID-19 patients. The research pinpointed key RBM epitopes (S431-454, S470-486, S501-515), with S470-486 emerging as an immunodominant target for diagnostics and therapeutics. Using phage display and ScFv libraries, the study validated epitope mapping and antibody functionality. Supported by AtaGenix’s expertise in phage display, protein expression, and assay development, this breakthrough offers a scalable approach for combating emerging viral pathogens, updated as of August 24, 2025.